Anlon Healthcare IPO Details
Anlon Healthcare is coming up with a book-built IPO of Rs. 121.03 crore, entirely through a fresh issue of 1.33 crore equity shares.
-
IPO Opens: 26 August 2025
-
IPO Closes: 29 August 2025
-
Basis of Allotment: 1 September 2025
-
Tentative Listing: 3 September 2025 on BSE & NSE
Price Band: Rs. 86 – Rs. 91 per share
Lot Size: 164 shares
-
Retail Minimum Investment: Rs. 14,104 (1 lot of 164 shares)
-
sNII Quota: 14 lots (2,296 shares) = Rs. 2,08,936
-
bNII Quota: 68 lots (11,152 shares) = Rs. 10,14,832
Book Running Lead Manager: Interactive Financial Services Ltd.
Registrar: Kfin Technologies Ltd.
Table of Contents
- GMP
- Reviews
- Subscription
- Allotment
Anlon Healthcare IPO latest updates
Grey market premium has not started
Anlon Healthcare IPO Key Dates
| Anchor portion | |
| IPO opens on | 26 August 2025 |
| IPO Closes on | 29 August 2025 |
| IPO Allotment on | 1 September 2025 |
| Unblocking of Asba | 2 September 2025 |
| Credit of Shares | 2 September 2025 |
| Listing of Shares | 3 September 2025 |
Who are the promoters of Anlon Healthcare IPO?
Punitkumar R. rasadia, Meet Atulkumar Vachhani and Mamata punitkumar Rasadia are the promoters of the company.
The promoters hold 70.26% shares in the post IPO capital of the company.
What are the Objects of Anlon Healthcare IPO?
The Offer comprises a Fresh Issue by the Company and an Offer for Sale by the Selling Shareholders.
The net proceeds of the Offer are proposed to be utilised in the following manner:
Funding capital expenditure requirements for Proposed Expansion Rs.30.72 Crore
Full or part repayment and/or prepayment of certain outstanding secured borrowingssecured borrowing (term loan)availed by the Company Rs. 5 Crore.
Funding the working capital requirements of the Company Rs. 43.15 Crore
General Corporate Purposes
About Anlon Healthcare Limited
Incorporated in 2013, Anlon Healthcare Limited is engaged in the manufacturing of Pharma Intermediates and Active Pharmaceutical Ingredients (APIs).
The company specializes in high-purity pharmaceutical intermediates (used for API production) and APIs that are widely used in medicines, nutraceuticals, personal care, and veterinary health products. All products comply with leading pharmacopeia standards — IP, BP, EP, JP, and USP.
Key Offerings
-
Pharma Intermediates: Cyanoethylbenzoic acid, Ketonitrile, Methyldesloratadine (used as key starting/advanced intermediates in API manufacturing).
-
APIs: Used in formulations such as tablets, capsules, ointments, syrups, nutraceuticals, personal care and veterinary medicines.
-
Custom Manufacturing: Complex chemicals with higher purity and reduced impurities, tailored to customer requirements.
Approvals & Regulatory Strength
-
Drug Master File (DMF) Approvals: Received from ANVISA (Brazil), NMPA (China), and PMDA (Japan) for APIs like Loxoprofen Sodium Dihydrate and Loxoprofen Acid.
-
21 DMFs already filed with global authorities; applications in process for Ketoprofen and Dexketoprofen Trometamol.
Product Pipeline
-
65 commercialized products
-
28 products at pilot stage
-
49 products in laboratory testing
Infrastructure & Team
-
4 dedicated laboratories for testing and process improvements
-
34-member technical team, including 24 science graduates
-
105 employees + 8 contract workers (as of Jan 31, 2025)
👉 This positions Anlon Healthcare as a growing pharma-chem player with a wide product portfolio, global compliance, and strong R&D backing.
Anlon Healthcare IPO Details
| IPO opens on | 26 August, 2025 |
| IPO closes on | 29 August, 2025 |
| Issue Type | Book Built Issue IPO |
| Issue Size | 133,00,000 Shares / Rs 121.03 Crore |
| * Fresh Issue | – Crore |
| * Offer for Sale | – |
| Face Value per share: | Rs. 10 |
| Price Band | Rs. 86-91 |
| Retail Discount | Rs 0 per share |
| Employee discount | Rs. – per share |
| Retail Lot Size | 164 Shares |
| Listing will at | BSE, NSE |
How are the shares offered in Anlon Healthcare IPO?
| Investor Category | Shares Offered |
| QIB Shares Offered | Not less than 75% of the Net Issue |
| Retail Shares Offered | Not more than 10% of the Net Issue |
| NII Shares Offered | Not Less than 15% of the Net Issue |
How can the shares be applied in Anlon Healthcare IPO?
| Application | Lots | Shares | Amount |
| Retail (Min) | 1 | 164 | ₹14,924 |
| Retail (Max) | 13 | 2,132 | ₹1,94,012 |
| S-HNI (Min) | 14 | 2,296 | ₹2,08,936 |
| S-HNI (Max) | 67 | 10,988 | ₹9,99,908 |
| B-HNI (Min) | 68 | 11,152 | ₹10,14,832 |
Anlon Healthcare IPO allotment Status
Allotment of this IPO will be announced on XXX
| Registered Office of the company Anlon Healthcare Ltd. 101/102, Silvercoin Complex, Opp.Crystal Mall, Kalawad Road, Rajkot, Gujarat, 360005 |
|
| Who are the Lead Managers of All Time Plastics IPO? Interactive Financial Services ltd |
|
| Registrar to IPO | |
| Kfin Technologies Limited |
Anlon Healthcare IPO Financial Snapshot
| Period Ended | 31-Jan-25 | 31-Mar-24 | 31-Mar-23 | 31-Mar-22 |
| Assets | 160.96 | 128 | 111.55 | 84.97 |
| Total Income | 77.37 | 66.69 | 113.12 | 57.54 |
| Profit After Tax | 11.96 | 9.66 | 5.82 | -0.11 |
| Net Worth | 71.86 | 21.03 | 7.37 | 1.55 |
| Reserves and Surplus | 32.01 | 5.03 | -4.63 | -10.24 |
| Total Borrowing | 62.39 | 74.56 | 66.39 | 60.32 |
| Amount in Rs. Crore | ||||
Key Performance Indicators
| KPI | Values |
| ROCE | 21.93% |
| Debt/Equity | 0.73 |
| RoNW | 25.21% |
| PAT Margin | 17.06% |
| EBITDA Margin | 26.88% |
| Price to Book Value | 4.51 |
| EPS | 6.38 |
| PER | 14.26 |
How Anlon Healthcare IPO compares with the Peers?
Peer Comparison.
| Company Name | P/E (x) | RoNW (%) |
| Anlon Healthcare Limited | 14.26 | 25.51 |
| Kronox Lab Sciences Limited | 26.18 | 28.26 |
| Acutaas Chemicals Limited | 58.47 | 12.15 |
| Supriya Lifescience Limited | 29.27 | 18.86 |
# This is only coverage of News related to Grey Market. We do not deal in grey market premium, nor we recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.
📝 Chanakya’s Show Verdict
by Paresh Gordhandas, CA & Research Analyst
👉 “Strong turnaround with rising profitability, improving balance sheet, and global regulatory approvals make Anlon Healthcare IPO attractive. However, debt levels remain on the higher side. Suitable for investors with a medium-to-long-term view. Moderate listing gains possible depending on subscription momentum.”
A. Moderate listing gains are possible if subscription response remains strong, given improving profitability and sector demand.
A. Fundamentally strong with global approvals and expanding product base. Recommended for medium-to-long-term investors; cautious traders may consider for listing play.
A. Turnaround story: from a small net worth of Rs. 1.55 cr in FY22 to Rs. 71.86 cr in Jan-25. PAT improved to Rs. 11.96 cr in Jan-25 despite high borrowings.
A. High debt burden, raw material price volatility, and revenue fluctuations pose risks to sustained growth.
A. Yes, retail investors with a 2–3 year horizon can consider this IPO. Listing gains are a bonus, but the real story lies in long-term growth.
